Monday, May 16, 2022 5:47:38 PM
I have owned and studied RVVTF. There is a very close comparison between the processes that RLFTF and RVVTF have been following. Different drugs, but very similar processes. IMO RVVTF won't see EUA approval until very late 2022 or early 2023 (assuming they meet their new primary end points). Clearly they failed to do so in the current trial (same thing happened to RLFTF).
Both RVVTF (as well as RLFTF) may prevail in the end, however the clock is ticking on the pandemic while other pharms have been getting FDA approvals. I've always felt that MF had placed his priorities on SHROOMS rather than Bucillamine, hence the slow start out of the gate once they got FDA approval to start Phase 3. That was the red flag for me and a big let down. Slow you blow, snooze you loose. Well, it's not too late, but he had better forgot about the shrooms and pull out all of the stops to push Bucillamine to the finish line!!
Kona Gold Beverages, Inc. Nears Completion of Reverse Merger with New Candidate • KGKG • Aug 12, 2024 10:00 AM
Maybacks Global Entertainment and DigiTrax Entertainment Sign Agreement to Broadcast "Karaoke Cloud" on iDreamCTV • AHRO • Aug 12, 2024 8:45 AM
HealthLynked Partners with RxSpark to Enhance Medication Access and Management for Patients • HLYK • Aug 12, 2024 8:00 AM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM